How Substance P and Neurokinin A Choose Their Receptors — and Sometimes Swap | Research

The takeaway

Two specific receptor regions — the ECL2 β-hairpin and N-terminal segment — determine whether tachykinin peptides bind their preferred NK1 or NK2 receptor, with chimeric constructs cleanly swapping specificity.

N-terminal positions 1-3 dispensable
The first three amino acids of substance P and neurokinin A are not needed for receptor binding — specificity is determined by the central peptide region interacting with two receptor hotspots

What the researchers found

The specificity and cross-reactivity of substance P (SP) and neurokinin A (NKA) at NK1R and NK2R is determined by interactions between the amino acids preceding the shared FxGLM consensus motif and two receptor regions: the β-hairpin of extracellular loop 2 (ECL2) and a segment of the N-terminus leading into transmembrane helix 1. Positively charged residues R177 (NK1R) and K180 (NK2R) in ECL2 play vital roles in these interactions.

The N-terminal positions 1–3 of the peptide ligands were entirely dispensable for receptor activation, meaning the selectivity determinants reside in the central peptide region. Mutated and chimeric receptor constructs, along with modified ligands, cleanly swapped specificity between NK1R and NK2R as predicted by the structural model, validating the structure-activity hypotheses.

Why it matters

NK1 and NK2 receptors are drug targets for pain, inflammation, nausea, and respiratory diseases. NK1 antagonists (like aprepitant for chemotherapy-induced nausea) are already approved. Understanding exactly why substance P prefers NK1 while neurokinin A prefers NK2 — and how to eliminate cross-reactivity — enables the design of more selective peptide agonists and antagonists with fewer off-target effects.

How the study worked

The researchers used a combination of molecular modeling, receptor mutagenesis, and chimeric receptor/ligand constructs to map the interactions underlying tachykinin receptor specificity. They modeled ligand-bound receptor complexes, identified key contact residues, and validated predictions by swapping residues between NK1R and NK2R to test whether peptide preferences changed accordingly. Functional assays confirmed the activation profiles of the engineered constructs.

What this study cannot tell us

The study is primarily computational and in vitro, relying on molecular modeling and cell-based assays rather than in vivo experiments. While the chimeric construct approach provides elegant proof-of-concept, the simplified receptor models may not capture all the complexities of receptor-ligand interactions in living tissues, where factors like membrane composition, receptor oligomerization, and accessory proteins can influence binding. The findings need validation in physiological settings.

How to read the evidence

This is a rigorous structure-activity relationship study combining molecular modeling with experimental validation through mutagenesis and chimeric constructs. The predictive power of the model (chimeric swaps behaving as expected) provides strong evidence for the proposed mechanism. However, all work is in vitro, and physiological validation is needed.

When this study was published

Published in 2023, this is a recent study that provides detailed molecular insights applicable to ongoing peptide drug development programs targeting tachykinin receptors.

The bigger picture

The tachykinin system is one of the oldest neuropeptide signaling systems in biology, involved in pain transmission, inflammation, mood regulation, and gut motility. Understanding the molecular basis of receptor selectivity across this peptide family has implications beyond NK1/NK2 — the principles apply to designing selective ligands for the entire GPCR superfamily, where cross-reactivity between related peptide ligands and receptors is a common challenge in drug development.

Questions still open

Can these structural insights be used to design substance P analogs with improved NK1 selectivity for treating pain and depression?
Do the ECL2 and N-terminal specificity determinants identified here extend to the NK3 receptor and its preferred ligand neurokinin B?
Could biased agonists targeting specific receptor regions achieve therapeutic effects while avoiding cross-receptor side effects?

Common questions

What are tachykinins and why are they important in medicine?

Tachykinins are a family of small neuropeptides — including substance P and neurokinin A — that transmit signals in the nervous system and immune system. Substance P is best known for carrying pain signals to the brain, but tachykinins also regulate inflammation, mood, nausea, and gut function. Drugs targeting tachykinin receptors are already used clinically (aprepitant for chemotherapy nausea blocks the NK1 receptor), and better understanding of how peptides select their receptors can lead to more precise medications.

Why does peptide cross-reactivity matter for drug design?

When a peptide drug meant to activate one receptor accidentally activates a related receptor, it can cause unwanted side effects. Substance P and neurokinin A share a common tail sequence (FxGLM) that helps both bind to tachykinin receptors, but they differ in their middle sections, which determines receptor preference. By identifying exactly which receptor and peptide features control this preference, scientists can engineer more selective drugs that activate only the intended target — delivering therapeutic benefits with fewer side effects.

Read the original research

Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors.

The Journal of biological chemistry, 299(12), 105438

View on PubMed ↗Publisher’s paper ↗

Citation

Madsen, Jesper J; Petersen, Jacob E; Christensen, Dan P; Hansen, Jakob B; Schwartz, Thue W; Frimurer, Thomas M; Olsen, Ole H. (2023). Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors.. The Journal of biological chemistry, 299(12), 105438. https://doi.org/10.1016/j.jbc.2023.105438